- Home
- FBRX vs SWKH Comparison
FBRX vs SWKH Comparison
Compare FBRX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- SWKH
- Stock Information
- Founded
- FBRX N/A
- SWKH 1996
- Country
- FBRX United States
- SWKH United States
- Employees
- FBRX N/A
- SWKH N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- SWKH Diversified Financial Services
- Sector
- FBRX Health Care
- SWKH Finance
- Exchange
- FBRX Nasdaq
- SWKH Nasdaq
- Market Cap
- FBRX 154.5M
- SWKH 176.0M
- IPO Year
- FBRX N/A
- SWKH 1999
- Fundamental
- Price
- FBRX $14.37
- SWKH $14.45
- Analyst Decision
- FBRX Strong Buy
- SWKH Strong Buy
- Analyst Count
- FBRX 3
- SWKH 1
- Target Price
- FBRX $68.00
- SWKH $18.00
- AVG Volume (30 Days)
- FBRX 103.4K
- SWKH 6.7K
- Earning Date
- FBRX 11-13-2025
- SWKH 11-13-2025
- Dividend Yield
- FBRX N/A
- SWKH N/A
- EPS Growth
- FBRX N/A
- SWKH 55.18
- EPS
- FBRX N/A
- SWKH 1.41
- Revenue
- FBRX N/A
- SWKH $37,409,000.00
- Revenue This Year
- FBRX N/A
- SWKH $52.93
- Revenue Next Year
- FBRX N/A
- SWKH N/A
- P/E Ratio
- FBRX N/A
- SWKH $10.20
- Revenue Growth
- FBRX N/A
- SWKH 47.31
- 52 Week Low
- FBRX $4.11
- SWKH $12.00
- 52 Week High
- FBRX $28.68
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- FBRX 57.28
- SWKH N/A
- Support Level
- FBRX $13.90
- SWKH N/A
- Resistance Level
- FBRX $15.49
- SWKH N/A
- Average True Range (ATR)
- FBRX 1.39
- SWKH 0.00
- MACD
- FBRX -0.04
- SWKH 0.00
- Stochastic Oscillator
- FBRX 46.66
- SWKH 0.00
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.